Skip to Content
MilliporeSigma
  • Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice.

Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice.

Journal of medicinal chemistry (2014-02-27)
José A Jara, Vicente Castro-Castillo, Jorge Saavedra-Olavarría, Liliana Peredo, Mario Pavanni, Fabián Jaña, María Eugenia Letelier, Eduardo Parra, María Inés Becker, Antonio Morello, Ulrike Kemmerling, Juan Diego Maya, Jorge Ferreira
ABSTRACT

Tumor cells principally exhibit increased mitochondrial transmembrane potential (ΔΨ(m)) and altered metabolic pathways. The therapeutic targeting and delivery of anticancer drugs to the mitochondria might improve treatment efficacy. Gallic acid exhibits a variety of biological activities, and its ester derivatives can induce mitochondrial dysfunction. Four alkyl gallate triphenylphosphonium lipophilic cations were synthesized, each differing in the size of the linker chain at the cationic moiety. These derivatives were selectively cytotoxic toward tumor cells. The better compound (TPP(+)C10) contained 10 carbon atoms within the linker chain and exhibited an IC50 value of approximately 0.4-1.6 μM for tumor cells and a selectivity index of approximately 17-fold for tumor compared with normal cells. Consequently, its antiproliferative effect was also assessed in vivo. The oxygen consumption rate and NAD(P)H oxidation levels increased in the tumor cell lines (uncoupling effect), resulting in a ΔΨ(m) decrease and a consequent decrease in intracellular ATP levels. Moreover, TPP(+)C10 significantly inhibited the growth of TA3/Ha tumors in mice. According to these results, the antineoplastic activity and safety of TPP(+)C10 warrant further comprehensive evaluation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Lactic Dehydrogenase from bovine heart, Type XVII, buffered aqueous glycerol solution, ≥400 units/mg protein
Sigma-Aldrich
L-Lactic Dehydrogenase from bovine heart, Type III, ammonium sulfate suspension, ≥500 units/mg protein
Sigma-Aldrich
L-Lactic Dehydrogenase from bovine muscle, Type X, ammonium sulfate suspension, ≥600 units/mg protein
Sigma-Aldrich
L-Lactic Dehydrogenase from porcine heart, ammonium sulfate suspension, ≥200 units/mg protein
Sigma-Aldrich
Lactic Dehydrogenase, recombinant from E. coli, ≥90 U/mg
Sigma-Aldrich
L-Lactic Dehydrogenase from bovine heart, 1000 units/mL
Sigma-Aldrich
L-Lactic Dehydrogenase from rabbit muscle, Type II, ammonium sulfate suspension, 800-1,200 units/mg protein
Sigma-Aldrich
L-Lactic Dehydrogenase from rabbit muscle, Type XI, lyophilized powder, 600-1,200 units/mg protein